ABVC BioPharma
ABVC
9 hedge funds and large institutions have $377K invested in ABVC BioPharma in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 4 closing their positions.
0.01% less ownership
Funds ownership: 0.2% → 0.18% (-0.01%)
18% less funds holding
Funds holding: 11 → 9 (-2)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
34% less capital invested
Capital invested by funds: $571K → $377K (-$194K)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$3.16K |
| 2 |
BlackRock
New York
|
+$1.88K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$273 |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$37 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$13.5K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$11K |
| 3 |
Jane Street
New York
|
-$10K |
| 4 |
Millennium Management
New York
|
-$10K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$628 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $235K | +$273 | +37 | +0.1% |
|
2
Geode Capital Management
Boston,
Massachusetts
| $87K | -$273 | -37 | -0.3% |
|
|
3
BlackRock
New York
| $25.8K | +$1.88K | +254 | +7% |
|
4
Northern Trust
Chicago,
Illinois
| $11.5K | – | – | – |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $9K | -$628 | -85 | -6% |
|
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $6.28K | -$13.5K | -1,826 | -65% |
|
|
7
UBS Group
Zurich,
Switzerland
| $2.69K | +$3.16K | +428 | New |
|
8
Wells Fargo
San Francisco,
California
| $75 | – | – | – |
|
|
9
Bank of America
Charlotte,
North Carolina
| $32 | +$37 | +5 | New |
|
|
10
Citadel Advisors
Miami,
Florida
| – | -$11K | -1,261 | Closed |
|
|
11
Jane Street
New York
| – | -$10K | -1,137 | Closed |
|
|
12
Millennium Management
New York
| – | -$10K | -1,101 | Closed |
|
ABVC Hedge Fund Activity: Q4 2022 in Review
9 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q4 2022, worth a combined $377K — down 34% from $571K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ABVC and 2 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 2 added.
The largest buyer was UBS Group, opening a new position worth an estimated $3.16K. The largest seller was Susquehanna International Group, cutting an estimated $13.5K.
- 9 institutional investors held ABVC BioPharma (ABVC) as of Q4 2022, down from 11 in Q3 2022.
- Funds reported $377K of ABVC BioPharma stock for Q4 2022, down 34% quarter-over-quarter.
- 2 funds opened new ABVC BioPharma positions in Q4 2022 and 4 closed out, a net change of -2 holders.
- The largest ABVC BioPharma buyer in Q4 2022 was UBS Group, an estimated $3.16K added.
- The largest ABVC BioPharma seller in Q4 2022 was Susquehanna International Group, an estimated $13.5K sold.
Based on aggregated 13F filings for Q4 2022.